Bristol Myers’ Opdivo Receives FDA Approval for Gastric Cancer

The U.S. Food and Drug Administration (FDA) recently approved Bristol Myers Squibb’s Opdivo for the initial treatment of certain types of cancer.

Opdivo, the trade name for the generic Nivolumab, can now be used in combination with certain types of chemotherapy for initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.